Slide 1: MIN-101C03 Update with Open Label, Extension Phase Data
MIN-101C03 Update with Open Label, Extension Phase Data October 26, 2016 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements about Minerva Neurosciences that are intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that a
Slide 3: MIN-101C03: Patient Disposition
MIN-101C03: Patient Disposition Placebo to MIN-1012 MIN-101 Placebo1 32 mg 64 mg Total 32 mg 64 mg Total Overall Screened Population N' = 342 Subjects Screened But Not Randomized 98 ( 28.7%) Randomized Population 42 41 83 78 83 161 244 Safety Population N'' = 39 N'' = 25 N'' = 19 N'' = 44 N'' = 78 N
Slide 4: Baseline for Patients who Crossed from Placebo to MIN-101
Baseline for Patients who Crossed from Placebo to MIN-101 is Start of Open Label (Week 12)
Slide 5: Negative Symptoms (Pentagonal Structure)
MIN-101C03: Negative Symptoms (Pentagonal Structure) Baseline for Placebo-to-MIN-101 is From Start of Open Label Core Phase Extension Phase Baseline for Placebo-to-MIN-101 is From Start of Open Label (Week 12)
Slide 6: Negative Symptoms (3-Factors)
MIN-101C03: Negative Symptoms (3-Factors) Baseline for Placebo-to-MIN-101 is From Start of Open Label Core Phase Extension Phase Baseline for Placebo-to-MIN-101 is From Start of Open Label (Week 12)
Slide 7: Brief Negative Symptom Score
MIN-101C03: Brief Negative Symptom Score Baseline for Placebo-to-MIN-101 is From Start of Open Label Core Phase Extension Phase Baseline for Placebo-to-MIN-101 is From Start of Open Label (Week 12)
Slide 8: Positive Symptoms (3-Factors)
MIN-101C03: Positive Symptoms (3-Factors) Baseline for Placebo-to-MIN-101 is From Start of Open Label Core Phase Extension Phase Baseline for Placebo-to-MIN-101 is From Start of Open Label (Week 12)
Slide 9: Total PANSS
MIN-101C03: Total PANSS Baseline for Placebo-to-MIN-101 is From Start of Open Label Core Phase Extension Phase Baseline for Placebo-to-MIN-101 is From Start of Open Label (Week 12)
Slide 10: Safety Results
Safety Results Findings MINERVA
Slide 11: Common Adverse Events (≥ 5% of Patients)
MIN-101C03: Common Adverse Events (≥ 5% of Patients) MIN-1012 System Organ Class Preferred Term Placebo1 (N = 83) 32 mg (N = 103) 64 mg (N = 102) Total (N = 205) Overall (N = 244) Subjects with Any Common TEAE 20 ( 24.1%) 24 ( 23.3%) 29 ( 28.4%) 53 ( 25.9%) 69 ( 28.3%) Investigations 0 ( 0.0%) 0 ( 0